NCT00822848 2018-09-07
Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma
OHSU Knight Cancer Institute
Phase 1 Completed
OHSU Knight Cancer Institute
Seagen Inc.
University of California, San Francisco
Abramson Cancer Center at Penn Medicine
Children's Oncology Group
University of California, San Francisco
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Fox Chase Cancer Center
Fox Chase Cancer Center